Program
sacituzumab tirumotecan
Also written as “Sacituzumab tirumotecan”, “SKB264” and “Sacituzumab Tirumotecan”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Breast Neoplasms · Ovarian Neoplasms · Endometrial Neoplasms, led by 4 companies.
Drug pageSacituzumab tirumotecan: every studyAll 113 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 2928 open or running | phase 3since Oct 3, 2023 | Apr 1, 2022 | May 10, 2027phase 3 · NCT06074588 |
| Sichuan Kelun Pharmaceuticalits history only | 1716 open or running | phase 3since Apr 15, 2022 | Apr 15, 2022 | Nov 2026phase 3 · NCT06448312 |
| Klus Pharmaits history only | 33 open or running | phase 2since Oct 29, 2019 | Oct 29, 2019 | Nov 30, 2027phase 2 · NCT05642780 |
| Convalife (Shanghai) | 11 open or running | phase 2since Aug 22, 2025 | Aug 22, 2025 | Aug 12, 2028phase 2 · NCT07157956 |
- Named in Merck’s own pipeline as
sacituzumab tirumotecan (MK-2870)
, phase 4, as of Nov 2, 2026 (source).
Also a collaborator on its studies: Daiichi Sankyo and Myriad Genetics.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseMerck licensed it from Kelun-Biotech, for everywhere outside Greater China.Source: Merck, Nov 4, 2025
How Klus Pharma and Convalife (Shanghai) relate to it is not in the registry or these sources.
History and studies of Convalife (Shanghai) only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Aug 6, 2023Named sacituzumab tirumotecanINNProposed as its International Nonproprietary Name in WHO's List 129 · before, SKB264
- Aug 22, 2025First study: phase 2 study in Advanced Solid TumorFirst studyNCT07157956 · 318 planned · China
Ahead
- Aug 12, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT07157956
TargetBeta
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugate…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) ”NCIt, by rule
Other programs on TACSTD2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sacituzumab govitecanrule | Gilead Sciences | phase 4 | 30 |
| datopotamab deruxtecanrule | AstraZeneca | phase 3 | 29 |
| JSKN016rule | Alphamab Oncology | phase 3 | 5 |
| Anti-TROP2 Antibody-drug Conjugate ESG401rule | Qilu Pharmaceutical | phase 3 | 3 |
| Anti-TROP-2/Topoisomerase Inhibitor ADC MHB036Crule | Minghui Pharmaceutical | phase 2 | 3 |
| sacituzumab drozuntecanrule | dualitybio-inc | phase 2 | 2 |
| Anti-TROP-2 Antibody-drug Conjugate OBI-902rule | obi-pharma-inc | phase 2 | 1 |
| Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103rule | avenzo-therapeutics-inc | phase 2 | 1 |
| Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule | Astellas Pharma | phase 2 | 1 |
| JSKN016HCrule | Alphamab Oncology | phase 1 | 1 |
| KH815rule | Chengdu Kanghong Pharmaceutical Group | phase 1 | 1 |
Studies
The one study Convalife (Shanghai) leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07157956Advanced Solid Tumor · China | 2 | Not yet recruiting | Aug 12, 2028 | 318 |
How it is read
Names in the registry
- “Sacituzumab tirumotecan”, 22 entries
- “SKB264”, 15 entries
- “Sacituzumab Tirumotecan”, 5 entries
- “SKB264+SKB118”, 2 entries
- “sac-TMT”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 14 studies
- Triple Negative Breast Neoplasms, 6 studies
- Breast Neoplasms, 3 studies
- Ovarian Neoplasms, 2 studies
- Endometrial Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.